Coronaviridae Infections - Pipeline Review, H2 2016

Published: Aug, 2016 | Pages: 101 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Coronaviridae Infections - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Coronaviridae Infections - Pipeline Review, H2 2016', provides an overview of the Coronaviridae Infections pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Coronaviridae Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Coronaviridae Infections and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Coronaviridae Infections
- The report reviews pipeline therapeutics for Coronaviridae Infections by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Coronaviridae Infections therapeutics and enlists all their major and minor projects
- The report assesses Coronaviridae Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Coronaviridae Infections

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Coronaviridae Infections
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Coronaviridae Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Coronaviridae Infections Overview 10
Therapeutics Development 11
Pipeline Products for Coronaviridae Infections - Overview 11
Pipeline Products for Coronaviridae Infections - Comparative Analysis 12
Coronaviridae Infections - Therapeutics under Development by Companies 13
Coronaviridae Infections - Therapeutics under Investigation by Universities/Institutes 15
Coronaviridae Infections - Pipeline Products Glance 16
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Coronaviridae Infections - Products under Development by Companies 19
Coronaviridae Infections - Products under Investigation by Universities/Institutes 21
Coronaviridae Infections - Companies Involved in Therapeutics Development 22
AstraZeneca Plc 22
CEL-SCI Corporation 23
GeneCure LLC 24
Gilead Sciences, Inc. 25
Hemispherx Biopharma, Inc. 26
Humabs BioMed SA 27
Inovio Pharmaceuticals, Inc. 28
Kineta, Inc. 29
Nanotherapeutics, Inc. 30
NanoViricides, Inc. 31
Novavax, Inc. 32
Organic Vaccines 33
Phelix Therapeutics, LLC 34
Planet Biotechnology Inc. 35
Protein Sciences Corporation 36
Regeneron Pharmaceuticals Inc 37
Coronaviridae Infections - Therapeutics Assessment 38
Assessment by Monotherapy Products 38
Assessment by Combination Products 39
Assessment by Target 40
Assessment by Mechanism of Action 42
Assessment by Route of Administration 44
Assessment by Molecule Type 46
Drug Profiles 48
CEL-1000 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
D-3252 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
Drugs to Inhibit Cathepsin L for Infectious Diseases - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
FBR-001 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
FDX-000 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
Gene Therapy for Severe Acute Respiratory Syndrome - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
GS-5734 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
INO-4500 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
interferon alfa-n3 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
interferon beta-1a - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
KIN-1400 - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
LCA-60 - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
Middle East respiratory syndrome coronavirus vaccine - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
Middle East respiratory syndrome coronavirus vaccine - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
Middle East respiratory syndrome coronavirus vaccine - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
Middle East respiratory syndrome vaccine - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
Middle East respiratory syndrome vaccine - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
Middle East respiratory syndrome vaccine + severe acute respiratory syndrome vaccine - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
ML-188 - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
Monoclonal Antibody for Coronavirus Infection - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
Monoclonal Antibody for SARS Virus Infections - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
RBD-219N1 - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
REGN-3048 - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
REGN-3051 - Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
SAB-301 - Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
SARS (virus like particle) vaccine - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
severe acute respiratory syndrome vaccine - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
Small Molecule for Middle East Respiratory Syndrome Human Coronavirus Infection - Drug Profile 83
Product Description 83
Mechanism Of Action 83
R&D Progress 83
Small Molecules for Viral Infections - Drug Profile 84
Product Description 84
Mechanism Of Action 84
R&D Progress 84
Small Molecules to Inhibit 3CLpro for Coronavirus Infections - Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
SSYA-10001 - Drug Profile 86
Product Description 86
Mechanism Of Action 86
R&D Progress 86
Coronaviridae Infections - Dormant Projects 87
Coronaviridae Infections - Discontinued Products 90
Coronaviridae Infections - Product Development Milestones 91
Featured News & Press Releases 91
Aug 11, 2016: Phase I Clinical Trials Underway for First MERS Treatment 91
Aug 08, 2016: GeneOne Life Science Announces Full Enrollment of First-In-Human Study of MERS Vaccine 92
Jan 20, 2016: Orphan Medicine Designation and European Medicines Agency Public Opinion Summary Published by EMA Regarding Alferon N Injection as a Treatment of Middle East Respiratory Syndrome 92
Nov 19, 2015: GeneOne Life Science and Inovio Pharmaceuticals' MERS Vaccine Approved for First-in-Human Study 93
Oct 19, 2015: Inovio and Partner Advance MERS Vaccine 93
Oct 19, 2015: Hemispherx Biopharma Europe Receives Positive Opinion on Application for Orphan Designation by the European Medicines Agency for Alferon N Injection to Treat Patients with Middle East Respiratory Syndrome 93
Jul 28, 2015: PNAS Paper Details Efficacy Of A Potent, Fully Human Antibody For The Treatment Of MERS 94
Jul 15, 2015: Hemispherx Biopharma Europe Submits Application for Orphan Medicine Designation to the EMA for Alferon N Injection for Treatment of Middle East Respiratory Syndrome 95
Jun 22, 2015: MERS coronavirus: Candidate vaccine gears up for clinical trials 95
Jun 04, 2015: Kineta's Novel Broad Spectrum Antivirals Trigger Effective Natural Immune Response to Flu and Respiratory Virus Infections 96
Jun 16, 2014: Hemispherx Announces New Publication With Potential Insight Into High Mortality Rate in Middle Eastern Respiratory Syndrome (MERS) 97
Apr 30, 2014: New Experimental Vaccine Produces Immune Response Against Middle East Respiratory Syndrome Coronavirus 98
Jun 06, 2013: Novavax Produces New Vaccine Candidate To Fight MERS-CoV Infection 99
Appendix 100
Methodology 100
Coverage 100
Secondary Research 100
Primary Research 100
Expert Panel Validation 100
Contact Us 100
Disclaimer 101

List of Tables

Number of Products under Development for Coronaviridae Infections, H2 2016 11
Number of Products under Development for Coronaviridae Infections - Comparative Analysis, H2 2016 12
Number of Products under Development by Companies, H2 2016 14
Number of Products under Investigation by Universities/Institutes, H2 2016 15
Comparative Analysis by Clinical Stage Development, H2 2016 16
Comparative Analysis by Early Stage Development, H2 2016 17
Comparative Analysis by Unknown Stage Development, H2 2016 18
Products under Development by Companies, H2 2016 19
Products under Development by Companies, H2 2016 (Contd..1) 20
Products under Investigation by Universities/Institutes, H2 2016 21
Coronaviridae Infections - Pipeline by AstraZeneca Plc, H2 2016 22
Coronaviridae Infections - Pipeline by CEL-SCI Corporation, H2 2016 23
Coronaviridae Infections - Pipeline by GeneCure LLC, H2 2016 24
Coronaviridae Infections - Pipeline by Gilead Sciences, Inc., H2 2016 25
Coronaviridae Infections - Pipeline by Hemispherx Biopharma, Inc., H2 2016 26
Coronaviridae Infections - Pipeline by Humabs BioMed SA, H2 2016 27
Coronaviridae Infections - Pipeline by Inovio Pharmaceuticals, Inc., H2 2016 28
Coronaviridae Infections - Pipeline by Kineta, Inc., H2 2016 29
Coronaviridae Infections - Pipeline by Nanotherapeutics, Inc., H2 2016 30
Coronaviridae Infections - Pipeline by NanoViricides, Inc., H2 2016 31
Coronaviridae Infections - Pipeline by Novavax, Inc., H2 2016 32
Coronaviridae Infections - Pipeline by Organic Vaccines, H2 2016 33
Coronaviridae Infections - Pipeline by Phelix Therapeutics, LLC, H2 2016 34
Coronaviridae Infections - Pipeline by Planet Biotechnology Inc., H2 2016 35
Coronaviridae Infections - Pipeline by Protein Sciences Corporation, H2 2016 36
Coronaviridae Infections - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 37
Assessment by Monotherapy Products, H2 2016 38
Assessment by Combination Products, H2 2016 39
Number of Products by Stage and Target, H2 2016 41
Number of Products by Stage and Mechanism of Action, H2 2016 43
Number of Products by Stage and Route of Administration, H2 2016 45
Number of Products by Stage and Molecule Type, H2 2016 47
Coronaviridae Infections - Dormant Projects, H2 2016 87
Coronaviridae Infections - Dormant Projects (Contd..1), H2 2016 88
Coronaviridae Infections - Dormant Projects (Contd..2), H2 2016 89
Coronaviridae Infections - Discontinued Products, H2 2016 90